M
Mineralys Therapeutics, Inc. (MLYS)
NMS – Real Time Price. Currency in USD
29.26
-0.47 (-1.58%)
At close: May 12, 2026, 4:00 PM EDT
29.26
0.00 (0.00%)
After-hours: May 12, 2026, 5:42 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
29.26
-0.47 (-1.58%)
At close: May 12, 2026, 4:00 PM EDT
29.26
0.00 (0.00%)
After-hours: May 12, 2026, 5:42 PM EDT
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
| Name | Position |
|---|---|
| Dr. Brian Taylor Slingsby M.D., M.P.H., Ph.D. | Founder & Executive Director |
| Dr. David M. Rodman M.D. | Chief Medical Officer |
| Dr. Robert McKean Ph.D. | Senior Vice President of CMC |
| Mr. Adam Scott Levy | CFO & Secretary |
| Mr. Eric J. Warren R.Ph. | Chief Commercial Officer |
| Mr. Jeffrey A. Munsie J.D. | Chief Legal Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-06 | 10-Q | mlys-20260331.htm |
| 2026-04-10 | ARS | mineralystherapeutics_2026.pdf |
| 2026-04-08 | DEFA14A | mlys-additionalproxymateri.htm |
| 2026-03-12 | 10-K | mlys-20251231.htm |
| 2026-03-09 | 8-K | mlys-20260306.htm |
| 2026-02-13 | S-8 | a2026forms-8.htm |
| 2026-01-06 | 8-K | mlys-20260106.htm |
| 2025-11-10 | 10-Q | mlys-20250930.htm |
| 2025-09-02 | S-3MEF | mlys-formsx3mef.htm |
| 2025-08-12 | 8-K | mlys-20250812.htm |
| Mr. Jon Congleton | President, CEO & Director |
| Ms. Danielle Mahoney | Senior Vice President of Quality Assurance |
| Ms. Jessica Ibbitson | Executive Vice President of Operations |
| Ms. Tiffany Ellen Burt | Senior Vice President of Medical Affairs |